Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

AIMS: Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary arter...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Shinya, Ogawa, Hisao, Takeuchi, Masaru, Flather, Marcus D., Bhatt, Deepak L.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Esc Fasttrack
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966970/
https://www.ncbi.nlm.nih.gov/pubmed/20805115
http://dx.doi.org/10.1093/eurheartj/ehq320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966970/
https://www.ncbi.nlm.nih.gov/pubmed/20805115
http://dx.doi.org/10.1093/eurheartj/ehq320

Ejemplares similares